

Date: April 28, 2026

To,

National Stock Exchange of India Limited

Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (East), Mumbai – 400051
Maharashtra, India.

Symbol: FABTECH

BSE Limited

Listing Department
Floor 25, P J Towers,
Dalal Street, Mumbai – 400001
Maharashtra, India.

Scrip Code: 544558

Dear Sir/Madam,

Sub: Investor Presentation

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Investor Presentation in relation to the Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2026.




Request you to take the same on record.

Thank you.

**Yours faithfully,
For Fabtech Technologies Limited**

Hemant Mohan Anavkar
Executive Director
DIN: 00150776

Encl.: As mentioned above



Fabtech[®]
Technologies Limited
Life Engineering[™]

Fabtech Technologies Limited

Q4 FY26 & FY26 Investor Presentation

Disclaimer

This presentation and the accompanying slides (the "Presentation"), which have been prepared by Fabtech Technologies Limited, (The Company) solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not a guarantee of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict.

These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company's ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company's market preferences and its exposure to market risks, as well as other risks.

The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.

Why Turnkey + In-House Manufacturing Matters

- In pharmaceutical, biopharma, and healthcare projects, choosing a turnkey partner with in-house **Process, Air & Water** manufacturing capabilities is no longer a preference, it is a strategic necessity.
- **Single Accountability, Zero Coordination Risk:** One partner owns design, engineering, manufacturing, installation, and validation, eliminating delays and vendor conflicts.
- **Precision-Controlled Environments In-House:** Process Equipment & Containment Systems (Process), Cleanrooms (Air) & Purified Water & Distribution (Water) are engineered under one ecosystem ensuring seamless integration and regulatory compliance.
- **Speed to Market:** In-house manufacturing drastically reduces dependency on imports and fragmented suppliers accelerating delivery, qualification, and commercial launch.
- **Regulatory Confidence:** A unified turnkey approach ensures every system meets global cGMP, WHO, EU-GMP, USFDA, and ISO standards from the first blueprint to final validation.
- **Cost Efficiency & Long-Term Reliability:** Integrated design-to-delivery reduces project cost overruns and safeguards long-term operational efficiency.




Global Turnkey Solutions Provider to the Life Sciences & Healthcare Sectors

- **Fabtech Technologies Limited (FTL)**, the flagship of the Fabtech Group, brings three decades of engineering excellence to deliver **start-to-finish** turnkey solutions for pharmaceutical, biotech, and healthcare facilities worldwide. With deep capabilities across **Process, Air & Water**, FTL integrates design, engineering, manufacturing, and validation to build GMP-compliant, energy-efficient, and contamination-controlled environments across **62 countries**.
- **Post-COVID, the MEA region's focus on pharmaceutical self-reliance** has accelerated FTL's growth trajectory. Derives **78% of revenue from MENA, GCC, and ECO Zone markets**, the Company expands through **FTS Cleanroom Systems LLC** and strategic joint ventures. FTL continues to strengthen its position as a preferred partner for critical facility infrastructure in the markets present.
- **Fabtech's asset-light, integrated model** combines in-house manufacturing, advanced project execution, and minimal third-party dependency to ensure **speed, quality, and consistency**. By mastering the pillars of **Bio-Clean Air, Pure Water, and Precision Process Systems**, FTL empowers nations to build **resilient, sustainable, and future-ready healthcare manufacturing ecosystems**.

FTL Ecosystem

Fabtech – Listed Main Board
"FABTECH"



Order Book & Strategic Update



Strong Order Book Position

- Consolidated order book **₹900 + Crore** as of **March 31, 2026**
- Provides **strong revenue visibility and growth momentum**



Strengthening Global Positioning

- Expanding presence in **high-growth sectors & geographies**
- Building a **scalable and diversified execution platform**



Outlook

Positive growth outlook driven by:

- **Robust order pipeline**
- **Geographic expansion**
- Focus on **complex, high-value projects**



Resilient Performance Amid Global Volatility

- Navigated **logistics disruptions, freight challenges, and input cost pressures**
- **Minimal impact** on overall performance
- Demonstrates **robust execution model and operational resilience**



Key Strategic Wins & Expansion

- **Animal Health Segment:** Successful entry and expansion
- **Saudi Arabia (KSA):** Secured **vaccine & advanced pharma projects**
- **Africa:** Won **large-scale pharma & infrastructure projects**

Strategic Project Wins Across High-Growth Markets

Fabtech continues to strengthen its global execution platform through high-value projects in Africa and Saudi Arabia, while expanding into high-potential sectors such as vaccines, animal health, and pharmaceutical manufacturing. The consolidated order book stands at ₹900+ crore as of March 31, 2026.



West Africa – Oral Solid Dosage (OSD) Facility

- **Project Value:** USD 7.05 million (~₹63.6 crore)
- **Scope:** Supply, installation, and commissioning of full infrastructure
- **Execution Timeline:** 23–27 months
- **Strategic Impact:** Expands Fabtech’s footprint in West Africa and supports local medicine manufacturing capacity.



Saudi Arabia – Animal Vaccine Project

- **Project Value:** USD 7.8 million (~₹65.5 crore)
- **Scope:** Turnkey cleanroom, HVAC, MEP, and utilities through to handover
- **Execution Timeline:** 11 months
- **Strategic Impact:** Marks entry into the high-growth animal health segment and strengthens presence in Saudi Arabia’s healthcare manufacturing market.



North Africa – Next-Generation Veterinary Facility

- **Project Value:** ₹49–52 crore
- **Scope:** Development of an EU-GMP-compliant veterinary formulations facility
- **Execution Timeline:** Targeted for completion by Q1 FY27
- **Strategic Impact:** Enables exports to the EU and neighbouring African markets, creating long-term regional reference value.



FY26 Operational Excellence, Future Readiness & Execution Report

Particulars (In ₹ Crore)	FY26	FY25	YoY Change
Total Income	431.33	335.94	+28.4%
EBITDA	55.56	46.97	+18.29%
Operational PAT	36.6	31.27	+17.4%
Cash & Bank Balances	208.57	35.01	+495.7%
Total Equity	419.77	173.11	+142.5%
FY26 Net Profit (PAT): ₹ 38.36 Cr			

Note: Adjusted for exceptional items (TSA) of ₹ 17.85 Cr (FY25) and ₹ 1.77 Cr (FY26)

- Revenue Growth & Scale:** Consolidated Total Income grew 28.4% YoY to ₹431.33 Cr, with ₹410.77 Cr revenue from operations, driven by strong international execution.
UAE Leadership: UAE became the largest market, contributing ₹126.66 Cr, followed by KSA at ₹82.72 Cr.
Kenya Expansion: Kenya revenue surged 236% YoY to ₹43.42 Cr, reflecting strong market expansion.
- Cash Flow Improvement:** Successfully swung from a negative operating cash flow of ₹(36.15) Cr in FY25 to a positive ₹0.48 Cr in FY26
- Debt Reduction:** Current borrowings reduced from ₹54.09 Cr to ₹42.20 Cr, strengthening financial stability.
- Strategic Expansion:** FY26 expanded beyond core execution through new projects, scalable infrastructure, and long-term capability building.
- GCC Localization:** UAE (₹126.66 Cr) and KSA (₹82.72 Cr) strengthened through local expansion, improving execution and regional positioning; receivables of ₹37.10 Cr (UAE) and ₹61.38 Cr (KSA) largely reflect project scale and standard collection cycles.

WE ARE COMMITTED TO SAVING LIVES



Fabtech[®]
Technologies Limited
Life Engineering™

Fabtech Technologies Limited

Registered Office: 715, Janki Center, Off Veera
Desai Road, Andheri West, Mumbai 400 053,
Maharashtra, India
Phone: +91 226 159 2900

Corporate Office: 1st Floor, ABR Emerald, Plot
No D8, Street 16, MIDC Andheri East, Chakala
MIDC, Mumbai – 400 093, Maharashtra, India.
Phone: +91 226 554 0300

Email: cs@fabtechnologies.com
Website: www.fabtechnologies.com



AKMIL Strategic Advisors Private Limited

Address: Office No. 1011, 10th Floor, Opal
Square, Road No. 16, Wagale Estate,
Thane (w)-400 604, Maharashtra, India
Phone: +91 98209 41925
Email: info@akmiladvisors.com
Website: www.akmiladvisors.com

THANK YOU